MCID: MLG074
MIFTS: 51

Malignant Mesenchymoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Malignant Mesenchymoma

MalaCards integrated aliases for Malignant Mesenchymoma:

Name: Malignant Mesenchymoma 12 49 14
Malignant Mesenchymal Tumor 49 41 69
Rat Malignant Renal Mesenchymal Tumor 69
Mesenchymoma, Malignant 12
Sarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5758
MeSH 41 C535700
NCIt 46 C4268
SNOMED-CT 64 89623007

Summaries for Malignant Mesenchymoma

MalaCards based summary : Malignant Mesenchymoma, also known as malignant mesenchymal tumor, is related to mesenchymoma and gallbladder sarcoma. An important gene associated with Malignant Mesenchymoma is MB (Myoglobin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 mesenchymoma 31.8 DES MB MDM2 MYOD1
2 gallbladder sarcoma 31.7 DES KIT MYOD1 MYOG
3 cystic nephroma 30.0 DES KIT WT1
4 conventional central osteosarcoma 30.0 EWSR1 MDM2
5 liposarcoma 29.8 CDK4 DES EWSR1 MB MDM2 TP53
6 suppressor of tumorigenicity 3 29.8 CDKN1A FHIT TP53
7 fibrosarcoma 29.7 CDKN1A DES ETV6 NTRK3
8 glioblastoma 29.4 CDK4 CDKN1A MDM2 TP53
9 sarcoma 29.4 EWSR1 KIT MDM2 SSX2B TP53
10 rhabdomyosarcoma 28.6 CDK4 DES EWSR1 MB MDM2 MYOD1
11 leiomyosarcoma 28.4 CDK4 DES KIT MB MDM2 MYOG
12 childhood malignant mesenchymoma 12.1
13 adult malignant mesenchymoma 12.1
14 giant cell myocarditis 10.6 DES MB
15 prostate embryonal rhabdomyosarcoma 10.6 KIT MYOD1
16 ovarian fibrothecoma 10.6 DES KIT
17 malignant triton tumor 10.5 DES MB MYOD1
18 spindle cell rhabdomyosarcoma 10.5 DES MB MYOD1
19 cervical polyp 10.5 DES MYOD1
20 adult mesoblastic nephroma 10.5 ETV6 NTRK3
21 spindle cell lipoma 10.5 CDK4 DES MDM2
22 spindle cell sarcoma 10.5 DES MDM2 NTRK3
23 mixed liposarcoma 10.5 CDK4 MB MDM2
24 alveolar soft part sarcoma 10.4 DES MB MYOD1
25 ischemic fasciitis 10.4 CDK4 DES MDM2
26 extraosseous osteosarcoma 10.4 CDK4 GALNT3 MDM2
27 lipomatosis, multiple 10.4 CDK4 DES MDM2
28 cutaneous ganglioneuroma 10.4 KIT NCAM1
29 congenital fibrosarcoma 10.4 DES ETV6 NTRK3
30 infiltrating angiolipoma 10.4 CDK4 MDM2
31 pediatric fibrosarcoma 10.4 ETV6 NTRK3
32 meninges sarcoma 10.4 MB TP53
33 sclerosing liposarcoma 10.4 MB MDM2 TP53
34 sarcomatoid squamous cell skin carcinoma 10.3 KIT MB TP53
35 mesenchymal cell neoplasm 10.3 EWSR1 KIT MYOD1
36 testicular gonadoblastoma 10.3 KIT WT1
37 myxosarcoma 10.3 MB MDM2 TP53
38 breast secretory carcinoma 10.3 CDK4 ETV6 NTRK3
39 malignant fibroxanthoma 10.3 CDK4 DES MDM2 MYOD1
40 mixed cell type cancer 10.3 KIT MB TP53
41 ring chromosome 7 10.3 CDK4 MDM2 TP53
42 orbital cancer 10.3 EWSR1 MB NCAM1
43 orbit rhabdomyosarcoma 10.3 MB MYOG
44 deep leiomyoma 10.3 CALD1 KIT
45 ewing's family of tumors 10.3 CDK4 EWSR1 KIT
46 periosteal osteogenic sarcoma 10.3 CDK4 MDM2 TP53
47 fallopian tube carcinosarcoma 10.3 NCAM1 WT1
48 grade iii astrocytoma 10.2 CDK4 MDM2 TP53
49 myositis 10.2 MB MYOD1 NCAM1
50 conventional fibrosarcoma 10.2 CALD1 KIT MDM2

Graphical network of the top 20 diseases related to Malignant Mesenchymoma:



Diseases related to Malignant Mesenchymoma

Symptoms & Phenotypes for Malignant Mesenchymoma

GenomeRNAi Phenotypes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 WT1 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.84 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 NTRK3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.84 SSX2B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 WT1 KIT NTRK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 SSX2B WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.84 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 WT1 KIT NTRK3 SSX2B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.84 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 KIT NTRK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.84 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 WT1 SSX2B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.84 SSX2B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 SSX2B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 KIT NTRK3 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT

MGI Mouse Phenotypes related to Malignant Mesenchymoma:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 MDM2 KIT MYOD1 MB UCHL1 NTRK3
2 growth/size/body region MP:0005378 10.36 GALNT3 MDM2 KIT MYOD1 MB MYOG
3 homeostasis/metabolism MP:0005376 10.35 MDM2 KIT MYOD1 MB MYOG UCHL1
4 cellular MP:0005384 10.29 MB GALNT3 MDM2 KIT TP53 NCAM1
5 mortality/aging MP:0010768 10.28 MDM2 KIT MYOD1 MB MYOG NCAM1
6 digestive/alimentary MP:0005381 10.24 MDM2 KIT UCHL1 PNLIP TP53 CDK4
7 hematopoietic system MP:0005397 10.24 MB GALNT3 MDM2 KIT TP53 UCHL1
8 embryo MP:0005380 10.18 MDM2 KIT MB TP53 MYOG WT1
9 integument MP:0010771 10.16 GALNT3 MDM2 KIT MYOG UCHL1 TP53
10 muscle MP:0005369 10.11 MDM2 KIT MYOD1 MB MYOG WT1
11 liver/biliary system MP:0005370 10.03 MDM2 KIT TP53 UCHL1 PNLIP WT1
12 neoplasm MP:0002006 9.97 MDM2 KIT MYOD1 WT1 TP53 CDK4
13 no phenotypic analysis MP:0003012 9.91 MDM2 KIT MYOD1 MYOG NTRK3 WT1
14 normal MP:0002873 9.81 MDM2 KIT MYOD1 TP53 MYOG NTRK3
15 renal/urinary system MP:0005367 9.56 GALNT3 MDM2 KIT TP53 UCHL1 WT1
16 respiratory system MP:0005388 9.28 KIT MYOD1 MB MYOG UCHL1 NTRK3

Drugs & Therapeutics for Malignant Mesenchymoma

Drugs for Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
3
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
4
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
7
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 46507594 772
9
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
12
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
13
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
16
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
17
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
18
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
20 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Vaccines Phase 4,Phase 1,Phase 2
27 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47
Tenofovir Phase 4,Phase 3,Not Applicable 147127-20-6 464205
48 calcium heparin Phase 4,Phase 1,Not Applicable
49 Lithium carbonate Phase 4,Not Applicable 554-13-2
50 Fibrinolytic Agents Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1718)

# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
6 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
7 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
8 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
9 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
10 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
11 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
12 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
13 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
14 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
15 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
17 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
18 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
19 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
20 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
21 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3 imatinib mesylate
22 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
23 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
24 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Unknown status NCT01091883 Phase 3
25 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
26 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
27 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
28 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
29 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
30 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
31 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
33 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
34 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
35 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
36 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
37 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
38 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
39 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
40 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
41 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
42 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
43 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
44 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
45 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
46 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
47 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
48 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
49 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
50 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)

Search NIH Clinical Center for Malignant Mesenchymoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: malignant mesenchymal tumor

Genetic Tests for Malignant Mesenchymoma

Anatomical Context for Malignant Mesenchymoma

MalaCards organs/tissues related to Malignant Mesenchymoma:

38
Bone, Lung, Heart, Kidney, Liver, Uterus, Prostate

Publications for Malignant Mesenchymoma

Articles related to Malignant Mesenchymoma:

(show top 50) (show all 121)
# Title Authors Year
1
Primary malignant mesenchymoma of bladder: Case report and review of the literature. ( 28796040 )
2017
2
Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review. ( 27102568 )
2016
3
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. ( 25132008 )
2014
4
Diagnosis and treatment considerations in a case of malignant mesenchymoma in an African fur seal (Arctocephalus pusillus). ( 23805568 )
2013
5
Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. ( 23082265 )
2012
6
Malignant mesenchymoma of the heart base in a dog with infiltration of the pericardium and metastasis to the lung. ( 22516086 )
2012
7
Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. ( 22833086 )
2012
8
Malignant mesenchymoma in the nasal cavity of a bull. ( 21306728 )
2011
9
An intra-abdominal malignant mesenchymoma associated with nonabsorbable sutures in a ferret (Mustela putorius furo). ( 20224105 )
2010
10
Malignant mesenchymoma surrounding the esophageal hiatus. ( 20103193 )
2010
11
Malignant mesenchymoma of the thyroid: case report and literature review. ( 20572598 )
2010
12
Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. ( 18781043 )
2008
13
Left atrial malignant mesenchymoma--emergency resection and mitral replacement. ( 17664193 )
2007
14
Uterine malignant mesenchymoma, arising in a leiomyoma, with pulmonary metastases. ( 17257144 )
2007
15
Intermandibular malignant mesenchymoma in a crossbreed dog. ( 16961475 )
2006
16
Malignant mesenchymoma arising from a uterine leiomyoma in the menopause. ( 15581987 )
2004
17
Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. ( 15601312 )
2004
18
Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. ( 15792374 )
2004
19
Malignant mesenchymoma of the orbit: case report and review of the literature. ( 12578773 )
2003
20
Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. ( 12792727 )
2003
21
Malignant mesenchymoma of the pleura. ( 17670075 )
2003
22
Malignant mesenchymoma of the uterus, arising in a leiomyoma. ( 11903599 )
2002
23
Retroperitoneal malignant mesenchymoma: a case of mesenchymal mixed tumor with osteosarcoma, leiomyosarcoma, liposarcoma and fibrosarcoma. ( 12514345 )
2002
24
Radical resection of a malignant mesenchymoma with hypogastric artery transposition. ( 12210036 )
2002
25
Primary malignant mesenchymoma of the heart. ( 11788281 )
2002
26
Malignant mesenchymoma of the lower leg. ( 11684725 )
2001
27
Giant malignant mesenchymoma of the spermatic cord with bidirectional differentiation. ( 11441285 )
2001
28
Retroperitoneal malignant mesenchymoma: imaging findings in five cases. ( 9933683 )
1999
29
Ring chromosomes in a malignant mesenchymoma. ( 10087943 )
1999
30
Malignant mesenchymoma arising in an incisional scar of the abdominal wall. ( 9800981 )
1998
31
Primary left atrial malignant mesenchymoma: a case report. ( 9607271 )
1998
32
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. ( 9657162 )
1998
33
Primary osteorhabdomyosarcoma (malignant mesenchymoma) of bone: a case report and review of the literature. ( 9346186 )
1997
34
Radiation-induced malignant mesenchymoma of the chest wall following treatment for breast cancer. ( 9166083 )
1997
35
Malignant mesenchymoma of the spermatic cord with a brief review of the literature. ( 9179703 )
1997
36
Maxillary malignant mesenchymoma and massive fibrous dysplasia. ( 9006514 )
1997
37
Malignant mesenchymoma arising from the prostate in Gardner's syndrome. ( 8776827 )
1996
38
Malignant mesenchymoma. ( 8630953 )
1996
39
Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. ( 9025898 )
1996
40
Clinical image. Malignant mesenchymoma of the buttock. ( 8933808 )
1996
41
Malignant mesenchymoma of the pleura. ( 8638184 )
1996
42
Malignant mesenchymoma as a primary urinary bladder tumour. ( 7767934 )
1995
43
Malignant mesenchymoma of the thigh. ( 7644947 )
1995
44
Primary malignant mesenchymoma of bone: case report, literature review, and distinction of this entity from mesenchymal and dedifferentiated chondrosarcoma. ( 7644944 )
1995
45
Panuveal malignant mesenchymoma. ( 7668945 )
1995
46
CT findings of retroperitoneal malignant mesenchymoma. ( 8161915 )
1994
47
Malignant mesenchymoma of the prostate: immunohistochemical and ultrastructural observations. ( 7941044 )
1994
48
Malignant mesenchymoma of the spermatic cord. ( 8088727 )
1994
49
A case of retroperitoneal malignant mesenchymoma. ( 7834083 )
1994
50
Retroperitoneal malignant mesenchymoma: a case report. ( 7614386 )
1994

Variations for Malignant Mesenchymoma

Expression for Malignant Mesenchymoma

Search GEO for disease gene expression data for Malignant Mesenchymoma.

Pathways for Malignant Mesenchymoma

Pathways related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 CDK4 CDKN1A FHIT KIT MDM2 TP53
2 12.78 CDK4 CDKN1A KIT MDM2 TP53
3
Show member pathways
12.57 CDK4 CDKN1A MDM2 TP53 UCHL1
4
Show member pathways
12.3 CDK4 CDKN1A MDM2 TP53
5 12.29 CDK4 CDKN1A MDM2 TP53
6 12.21 CDK4 CDKN1A MDM2 TP53
7
Show member pathways
12.16 CDK4 CDKN1A MDM2 TP53
8
Show member pathways
12.09 CDK4 CDKN1A MDM2 NTRK3 TP53
9 12.06 CDK4 CDKN1A MDM2 TP53
10
Show member pathways
12.03 CDK4 CDKN1A MDM2 TP53
11 11.95 CDK4 CDKN1A MDM2 TP53
12 11.8 CDK4 CDKN1A MDM2 TP53
13
Show member pathways
11.77 CDKN1A MDM2 TP53
14 11.74 CDKN1A MDM2 TP53
15 11.71 CDKN1A KIT MYOD1
16 11.7 CDK4 CDKN1A MYOD1
17 11.7 CDK4 CDKN1A FHIT TP53
18 11.66 CDKN1A MDM2 TP53
19 11.61 CDK4 CDKN1A MDM2 TP53
20 11.6 KIT NTRK3 TP53
21 11.51 CDKN1A MDM2 MYOD1
22 11.49 CDK4 CDKN1A MDM2 TP53
23 11.46 CDKN1A TP53 UCHL1
24 11.44 CDKN1A ETV6 EWSR1 MDM2 SSX2B TP53
25 11.34 DES KIT MYOD1 MYOG NCAM1
26 11.3 CDKN1A MYOD1 TP53
27 11.22 CDK4 CDKN1A MDM2 TP53
28 11.18 CDK4 CDKN1A TP53
29 11.16 CDK4 MDM2 TP53
30 11.1 CDK4 CDKN1A MDM2 TP53
31
Show member pathways
10.92 CDKN1A MDM2 TP53
32 10.73 CDKN1A TP53
33
Show member pathways
10.5 CDKN1A TP53

GO Terms for Malignant Mesenchymoma

Cellular components related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 CALD1 CDK4 CDKN1A DES ETV6 FHIT
2 transcription factor complex GO:0005667 9.26 CDK4 MYOD1 MYOG TP53
3 nucleolus GO:0005730 9.17 CDK4 CDKN1A ETV6 EWSR1 MDM2 TP53

Biological processes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.76 MB MDM2 NTRK3 WT1
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.58 CDKN1A MDM2 TP53
3 myotube differentiation GO:0014902 9.49 MYOD1 MYOG
4 replicative senescence GO:0090399 9.48 CDKN1A TP53
5 positive regulation of skeletal muscle fiber development GO:0048743 9.43 MYOD1 MYOG
6 positive regulation of cell cycle GO:0045787 9.43 CDK4 MDM2 TP53
7 muscle cell fate commitment GO:0042693 9.37 MYOD1 MYOG
8 signal transduction by p53 class mediator GO:0072331 9.32 CDKN1A TP53
9 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
10 cellular response to gamma radiation GO:0071480 9.13 CDKN1A MDM2 TP53
11 response to hyperoxia GO:0055093 8.8 CDK4 CDKN1A TP53

Molecular functions related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.46 ETV6 MYOD1 MYOG TP53
2 p53 binding GO:0002039 9.13 MDM2 NTRK3 TP53
3 ubiquitin protein ligase binding GO:0031625 9.1 CDKN1A FHIT MDM2 MYOD1 TP53 UCHL1

Sources for Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....